Long-term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics

Keyphrases

• Pharmacokinetics 100%
• Tolerability 100%
• Pulmonary Arterial Hypertension 100%
• Oral Treprostinil 100%
• Daily Dose 83%
• Adverse Events 50%
• 6-minute Walk Distance (6MWD) 50%
• Twice Daily 33%
• Prostacyclin 33%
• Single Center 16%
• Lung 16%
• High Dose 16%
• Clinical High Risk 16%
• Placebo-controlled 16%
• Intermediate Risk 16%
• Low Risk 16%
• Drug Levels 16%
• Open-label Extension 16%
• Exercise Tolerance 16%
• Increased Dose 16%
• Vascular Disease 16%
• Uncontrolled Study 16%
• Total Daily Dose 16%
• Efficacy Index 16%
• Trough Level 16%
• Prospective Parent 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Tolerability 100%
• Pharmacokinetics 100%
• Pulmonary Hypertension 100%
• Treprostinil 100%
• Adverse Event 50%
• Prostacyclin 33%
• Placebo 16%
• Pulmonary Vascular Disease 16%
• Insulin 16%
• Trough Level 16%